Huntington's Disease — Animal Models & Behavioral Testing

The best model depends on your research question. R6/2 is ideal for high-throughput drug screening due to its rapid onset (motor deficits by 5–6 weeks) and short lifespan. YAC128 and BACHD offer slower, more human-like progression suitable for longitudinal studies. The 3-NP toxin model provides rapid striatal lesions without requiring transgenic colonies, making it useful for neuroprotection studies targeting mitochondrial dysfunction.

R6/2 expresses only exon 1 of human huntingtin (a fragment model), producing rapid-onset, aggressive pathology with death by 12–16 weeks. YAC128 and BACHD are full-length models expressing the entire human HTT gene, resulting in slower disease progression over months. Full-length models exhibit more selective striatal neurodegeneration and metabolic disturbances that better recapitulate the human disease course, but require longer study timelines.

The core motor battery includes the rotarod test (progressive coordination decline), grip strength (neuromuscular weakness), and open field (locomotor activity). Balance beam and gait analysis add sensitivity for detecting subtle motor changes. For cognitive assessment, novel object recognition and Y-maze test recognition and working memory respectively — these are especially important for full-length models where cognitive deficits precede motor onset.

3-Nitropropionic acid (3-NP) is a mitochondrial complex II inhibitor that produces selective bilateral striatal lesions when administered systemically. It mimics the energy metabolism deficits and selective striatal neuronal death seen in HD without requiring genetic manipulation. Use 3-NP when studying mitochondrial dysfunction, oxidative stress, or neuroprotection, or when you need a rapid lesion model without maintaining a transgenic colony.

BACHD uses 97 mixed CAA/CAG repeats to solve the repeat instability problem that affects pure CAG models. Pure CAG repeat tracts are prone to somatic and germline expansion or contraction across generations, requiring constant genotyping to confirm repeat length. The mixed repeat sequence encodes the same polyglutamine tract but is genetically stable, ensuring consistent pathology across breeding generations without repeat length drift.

Cognitive deficits appear before motor onset in most full-length models, mirroring human HD. In YAC128, recognition memory deficits are detectable by 2–3 months, well before rotarod deficits at 6 months. In R6/2, cognitive impairments appear by 3–4 weeks due to the aggressive pathology. The 3-NP model produces cognitive deficits 1–2 weeks after striatal lesion induction, depending on lesion severity.

Yes, and this is recommended. A well-designed battery runs cognitive tests (novel object recognition, Y-maze) before motor tests (rotarod, grip strength, balance beam) to minimize motor confounds on cognitive readouts. Test order matters: low-stress, no-training-required assays first (open field, NOR, Y-maze), then trained motor tasks (rotarod, balance beam). Allow 48–72 hours between tests to reduce carry-over stress effects.

R6/2 is on a mixed C57BL/6 x CBA background, while YAC128 and BACHD are on FVB/N. FVB/N mice carry a retinal degeneration allele (Pde6b-rd1) causing blindness by weaning age, which affects any visually dependent task. Avoid the Morris Water Maze with FVB/N-background models and use tactile-cue-based or non-visual assays instead. Some labs backcross YAC128 or BACHD to C57BL/6J to eliminate this confound, but this changes the phenotype timeline.